Genomics and rare drug reactions
Executive Summary
Genomics are an important next step to improving predictive approaches to early testing for idiosyncratic, rare drug reactions, said C. George Rochester, lead mathematical statistician for the Quantitative Safety and Pharmacoepidemiology Group at CDER, at a recent drug safety meeting hosted by DIA and PhRMA. "If we look at the field of ... statistical genetics, that has a lot of big hope; there's a lot of emphasis on genomics and the hope that genomics is going to answer maybe almost all our questions," Rochester said. While admitting that genomics won't answer every question, looking at how proteins bond and behave has a lot of promise, he said. Rochester also stressed the importance of finding a multidisciplinary approach to improving predictive markers. Issam Zineh recently replaced Felix Frueh as FDA Associate Director for Genomics in the Office of Clinical Pharmacology in the Office of Translational Sciences (1"The Pink Sheet," Nov. 3, 2008, In Brief)
You may also be interested in...
New top genomics official at FDA
Issam Zineh replaces Felix Frueh as FDA Associate Director for Genomics in the Office of Clinical Pharmacology in the Office of Translational Sciences. Zineh comes from the University of Florida's Pharmacogenomics Center, where he was associate director. His specialty is the immunomodulatory effects and pharmacogenomics of cardiovascular and endocrine drugs. Frueh has joined Medco Health Solutions as vice president of research and development, personalized medicine
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.